NOTE FROM TED: Please do not look to this talk for medical or diagnostic advice and always consult a medical professional. This talk only represents the speaker's personal views and understanding of AI models and healthcare which warrants further scientific investigation. TEDx events are independently organized by volunteers. The guidelines we give TEDx organizers are described in more detail here: http://storage.ted.com/tedx/manuals/tedx_content_guidelines.pdf Why does modern medicine still miss so many di ...

Patient Focused. Discovery Driven. Accelerating personalized medicine in autoimmune disease Q4 & FY 2025 UPD ATE | MARCH 10, 20 26 Disclaimer 2 Identifying autoimmune disease is a challenge… Ambiguous symptoms Manifestations overlap Tests lack specificity, sensitivity Outdated tech, testing delays High rate of misdiagnosis With rheumatoid arthritis2 ~1M Americans diagnosed with lupus1 ~2M >41M A M E R I C A N S A N A + ANA+: antinuclear antibody positive, first-line screen for autoimmune disease 3 3 1. lupu ...

Imagine being told that a vital organ inside you could fail. But the treatment that you receive to refix your organ was never designed with you in mind. Take a moment. Look at the person to your right. Look at their shoes. Look at the person to your left. Look at their shoes. They're all different, right? By and large, men's and women's shoes are different. Some fit really well, some not so well. Some are built for comfort, others not so much. Surely, you want a medical device implanted in you, a life-savin ...

Core Viewpoint - The latest quarterly results for Hims and Hers show mixed performance, with a notable focus on the impact of GLP1-related issues and a shift back to core business areas [2][4][5]. Financial Performance - Earnings per share (EPS) for the quarter were reported at 8 cents, which is double the street's expectations [2]. - Revenue for Q4 was approximately $617 million, slightly below the expected $619 million, with forward guidance for Q1 projected between $600 million to $625 million, lower than Wall Street's expectation of $654 million [3][4]. Business Strategy - Hims and Hers is pivoting away from a heavy reliance on GLP1 products, emphasizing growth in their sexual health and dermatology segments, which grew over 30% [5]. - The company has a subscriber base of 2.5 million, with only a small portion using GLP1s, indicating a broader business model beyond this product line [5]. Market Challenges - The company faces legal and regulatory challenges, particularly related to a lawsuit from Nova Nordisk, which may limit stock valuation in the near term [8]. - There is a noted decline in investor enthusiasm for Hims and Hers, primarily due to diminishing excitement around GLP1 products and pricing pressures [9]. Future Outlook - The addressable market for GLP1s is expected to grow, but Hims and Hers' lack of access to these products is seen as a significant disadvantage [10][12]. - The company is focusing on a personalized medicine strategy, which includes lab tests to tailor medications, indicating potential for growth despite current challenges [14].

Industry Overview - Genomics is the comprehensive study of genomes, which has intensified interest among pharmaceutical and biotechnology companies for deeper insights into disease biology and effective therapeutic strategies [1] - The global genomics market was valued at $34.23 billion in 2025 and is projected to grow from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% [8] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to reach $69.18 billion by 2033, with a CAGR of 17.7% from 2026 to 2033 [8] Genomic Research and Applications - Insights from genomic research are increasingly used to evaluate patient responses to specific drugs, driving the development of targeted treatments and advancing personalized medicine [3] - The emergence of genome-editing technologies, particularly CRISPR/Cas9 systems, is enabling precise modifications to DNA, offering potential cures for diseases caused by genetic mutations [7] Key Companies - Illumina (ILMN) is a prominent player in genomic sequencing, recognized for its leadership in sequencing and array-based technologies [5] - Pacific Biosciences of California (PACB) focuses on advanced sequencing solutions and has seen its shares rise by 9.1% in the past year, currently holding a Zacks Rank 1 (Strong Buy) [10][12] - Caribou Biosciences (CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company, with shares surging 34.4% in the past year and a Zacks Rank 2 (Buy) [12][14] - Sana Biotechnology (SANA) is developing cell engineering platforms for diseases like type 1 diabetes and has seen its shares increase by 37.5% over the past year, also holding a Zacks Rank 2 [15][17]

Core Insights - Oryzon Genomics, a clinical-stage biopharmaceutical company, is a leader in epigenetics and focuses on personalized medicine for CNS disorders and oncology [3] Upcoming Events - Oryzon management will participate in several upcoming events, including: - Bio-Neuroscience 2026 from February 24-27 in Amsterdam - SmallCap Event 20 Edition on March 17 in Paris - BIO-Europe Spring 2026 from March 23-25 in Lisbon - LSX World Congress Europe on March 25-26 in Lisbon, where a panel discussion is scheduled for March 25 at 14:00 GMT [1][2] Company Overview - Founded in 2000 and headquartered in Barcelona, Oryzon has a strong clinical portfolio centered around two LSD1 inhibitors: - Vafidemstat, which is Phase III-ready for CNS programs - Iadademstat, which is in ongoing Phase I and II studies for oncology/hematology, showing a 100% overall response rate in first-line acute myeloid leukemia [3] - The company is also advancing a broader epigenetics pipeline, including a clinical candidate ORY-4001 for Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis [3] - Oryzon has a robust platform for biomarker identification and target validation across various malignant and neurological diseases [3]

邱锂力讲述了研发无接触监测系统，利用普通设备如手机、智能音箱等捕捉呼吸、心跳等身体信号，精度达毫米级，旨在将健康管理从被动就医转向主动守护。邱锂力作为UT Austin 教授, 曾任微软亚洲研究院副院长，她经过持续努力破解难题，获得技术突破包括声学超表面增强感知距离、毫米波成像实现便携式诊断，以及无创血糖检测替代传统扎针方法，初步结果与侵入式测量一致。多模态数据融合进一步全面理解健康状况，推动个性化医疗的科学预防，将“治已病”变成“治未病”。赋能未来医疗更主动、高效，减少对医院的依赖，为全球患者提供温暖、智能的健康伴侣。期待通过持续的探索与创新，能够帮助改善更多人的生活。 Dr. Lili Qiu, a professor at UT Austin and former Assistant Managing Director of Microsoft Research Asia, has developed a non-contact monitoring system. This system utilizes common devices like smartphones and smart speake ...

Core Insights - Oryzon Genomics has appointed Dr. Rolando Gutierrez-Esteinou as Chief Medical Officer for CNS Programs, bringing over 20 years of experience in neuroscience and psychiatry drug development [1][2][3] - Dr. Gutierrez-Esteinou will lead the Phase III clinical development of vafidemstat, targeting agitation and aggression in borderline personality disorder, while also expanding its use in autism spectrum disorder and schizophrenia [2][4] - Oryzon is recognized as a leader in epigenetics, focusing on personalized medicine for CNS disorders and oncology, with a clinical portfolio that includes two LSD1 inhibitors [5][6] Company Overview - Oryzon Genomics, founded in 2000 and headquartered in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics [5] - The company has a strong clinical portfolio, including vafidemstat, which is Phase III-ready, and iadademstat, which is in ongoing Phase I and II studies with promising results in acute myeloid leukemia [5][6] - Oryzon is advancing a broader epigenetics pipeline, including a clinical candidate for Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis [6]

#Microsoft #AI #aiinhealthcare #FutureOfAI #aiethics #Series #personalizedmedicine Give this a second thought: Some of today’s most advanced cancer immunotherapies work for only 30–40% of patients. Futurist Sinead Bovell explores with Microsoft’s Jonathan Carlson how AI is helping to unlock a new era of personalized medicine. Subscribe to Microsoft on YouTube here: https://aka.ms/SubscribeToYouTube Follow us on social: LinkedIn: https://www.linkedin.com/company/microsoft/ Twitter: https://twitter.com/Micros ...

Core Insights - Interpace Biosciences reported preliminary 2025 thyroid testing revenue growth of 21% compared to the previous year, with total revenue estimated at approximately $38-39 million, of which $34-35 million is attributed to thyroid testing [3][4] - The company has initiated guidance for 2026, projecting a revenue of approximately $40 million, representing a 16% growth in thyroid testing revenue over 2025 [4] - All preferred stock has been converted to common stock, simplifying the capital structure and resulting in approximately 27.7 million shares outstanding [5][6] - Interpace has a debt-free balance sheet and is operating with positive net income and EBITDA [7] - The company plans to seek an uplisting on the Nasdaq Stock Market in 2026, aiming to attract more investors and facilitate growth [7][8] Revenue Performance - Preliminary 2025 revenue from continuing operations is approximately $38-39 million, with thyroid testing contributing around $34-35 million [3] - The growth in thyroid testing revenue is approximately 21% over 2024 [3] - For 2026, the company anticipates revenue of about $40 million, with 100% derived from thyroid testing, indicating a projected growth of 16% [4] Capital Structure - In October 2024, all Series C Preferred shares were converted into common stock, resulting in the issuance of approximately 23,267,327 shares [5] - Following the conversion, the total pro forma basic shares outstanding is approximately 27.7 million [6] - Major shareholders include 1315 Capital with approximately 34% and Ampersand with about 50% of the outstanding common stock [6] Strategic Plans - The conversion of preferred stock and the elimination of debt are seen as pivotal milestones in the company's capital structure [7] - The company aims to leverage its simplified capital structure to focus on scaling its profitable thyroid diagnostics business [7] - Plans for uplisting to the Nasdaq are intended to enhance investor participation and support growth initiatives in sales and research [8]